Insider Selling: Zai Lab (NASDAQ:ZLAB) CEO Sells $428,520.78 in Stock

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CEO Ying Du sold 24,543 shares of the business’s stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $17.46, for a total transaction of $428,520.78. Following the completion of the sale, the chief executive officer owned 1,192,840 shares of the company’s stock, valued at approximately $20,826,986.40. This represents a 2.02% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Ying Du also recently made the following trade(s):

• On Tuesday, June 30th, Ying Du sold 7,026 shares of Zai Lab stock. The shares were sold at an average price of $18.53, for a total transaction of $130,191.78.
• On Thursday, May 14th, Ying Du sold 50,000 shares of Zai Lab stock. The shares were sold at an average price of $20.09, for a total transaction of $1,004,500.00.
• On Monday, April 6th, Ying Du sold 2,653 shares of Zai Lab stock. The stock was sold at an average price of $20.45, for a total transaction of $54,253.85.
• On Thursday, April 2nd, Ying Du sold 5,576 shares of Zai Lab stock. The stock was sold at an average price of $20.39, for a total value of $113,694.64.

Zai Lab Trading Up 0.8%

Shares of NASDAQ ZLAB opened at $19.15 on Thursday. Zai Lab Limited Unsponsored ADR has a 12-month low of $15.96 and a 12-month high of $41.20. The stock’s fifty day simple moving average is $19.07 and its two-hundred day simple moving average is $18.97. The stock has a market capitalization of $2.17 billion, a PE ratio of -11.82 and a beta of 0.78.

Zai Lab (NASDAQ:ZLAB) last released its quarterly earnings results on Wednesday, April 1st. The company reported ($0.50) EPS for the quarter. Zai Lab had a negative return on equity of 24.32% and a negative net margin of 39.29%.The company had revenue of $99.61 million during the quarter. On average, equities analysts predict that Zai Lab Limited Unsponsored ADR will post -2.23 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Zai Lab

An institutional investor recently raised its position in Zai Lab stock. SG Americas Securities LLC grew its stake in shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) by 6.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,396 shares of the company’s stock after acquiring an additional 642 shares during the quarter. SG Americas Securities LLC’s holdings in Zai Lab were worth $183,000 as of its most recent SEC filing. Institutional investors and hedge funds own 41.65% of the company’s stock.

Analyst Upgrades and Downgrades

ZLAB has been the subject of several analyst reports. Citigroup decreased their price target on shares of Zai Lab from $47.00 to $44.00 and set a “buy” rating for the company in a research report on Friday, May 8th. JPMorgan Chase & Co. reduced their price objective on shares of Zai Lab from $39.00 to $32.00 and set an “overweight” rating for the company in a research note on Wednesday, March 18th. Weiss Ratings raised shares of Zai Lab from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, June 26th. Finally, Wall Street Zen downgraded shares of Zai Lab from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $40.00.

Zai Lab Company Profile

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.